CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Class III antiarrhythmic
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises dronedarone, so inhibitors of this enzyme raise its levels. The strong inhibitor ketoconazole increased dronedarone levels 17-fold (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Darunavir is taken only with a booster (ritonavir or cobicistat), and in this regimen it slows the clearance of drugs that depend heavily on CYP3A (darunavir SmPC, EMA). The pair has not been studied, but the darunavir documents expect dronedarone levels to rise (darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; darunavir label, US Food and Drug Administration, FDA). Dronedarone prolongs the QT interval on the electrocardiogram (ECG), and the prolongation increases with its concentration (dronedarone FDA label). Dronedarone itself is a moderate CYP3A4 inhibitor and a potent inhibitor of the transporter P-glycoprotein (dronedarone SmPC, EMA). CYP3A inhibitors, in turn, may slow the clearance of darunavir and ritonavir and raise their levels (darunavir SmPC, EMA).
Symptoms
Higher dronedarone levels may lead to serious, including life-threatening, reactions such as heart rhythm disorders (darunavir label, US Food and Drug Administration, FDA; ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). QT prolongation causes no symptoms by itself and shows only on the electrocardiogram (ECG). Dronedarone may cause arrhythmias when proarrhythmic drugs are added or when electrolyte disturbances develop (dronedarone SmPC, EMA).
Management
The combination is contraindicated. Dronedarone is on the darunavir contraindication list with either booster (ritonavir or cobicistat), including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US labels of darunavir with ritonavir and with cobicistat also contraindicate dronedarone (darunavir labels, US Food and Drug Administration, FDA). Ritonavir, the darunavir booster, is itself incompatible with dronedarone. Dronedarone is on the ritonavir contraindication list (ritonavir SmPC, EMA, and FDA label). Ritonavir is among the strong CYP3A4 inhibitors on the dronedarone contraindication list (dronedarone SmPC, EMA, and FDA label). Before and during darunavir treatment, review all concomitant medicines for interactions (darunavir FDA label). If dronedarone and darunavir have nevertheless been taken together, monitor heart rhythm and blood pressure and give symptomatic and supportive treatment. There is no specific antidote, and it is not known whether dialysis removes dronedarone (dronedarone SmPC, EMA). Stop dronedarone if the QTc interval on the electrocardiogram (ECG) reaches 500 milliseconds or more. Correct any potassium or magnesium deficiency before starting dronedarone and during treatment (dronedarone SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3